Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Price, Quote, News and Overview

NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD

0.6371  +0.03 (+5.22%)

After market: 0.6386 +0 (+0.24%)

UNCY Quote, Performance and Key Statistics

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (5/7/2025, 8:00:02 PM)

After market: 0.6386 +0 (+0.24%)

0.6371

+0.03 (+5.22%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.16
52 Week Low0.2
Market Cap76.27M
Shares119.71M
Float113.35M
Yearly Dividend0.01
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-20 2025-05-20/amc
IPO06-17 2021-06-17


UNCY short term performance overview.The bars show the price performance of UNCY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

UNCY long term performance overview.The bars show the price performance of UNCY in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of UNCY is 0.6371 USD. In the past month the price increased by 35.52%. In the past year, price decreased by -43.62%.

UNICYCIVE THERAPEUTICS INC / UNCY Daily stock chart

UNCY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.31 332.73B
AMGN AMGEN INC 13.29 148.31B
GILD GILEAD SCIENCES INC 12.78 123.13B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.78B
REGN REGENERON PHARMACEUTICALS 12.66 60.56B
ARGX ARGENX SE - ADR 327.86 38.04B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.97B
ONC BEIGENE LTD-ADR N/A 25.03B
BNTX BIONTECH SE-ADR N/A 22.31B
NTRA NATERA INC N/A 21.77B
SMMT SUMMIT THERAPEUTICS INC N/A 18.04B
BIIB BIOGEN INC 7.41 17.17B

About UNCY

Company Profile

UNCY logo image Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Company Info

UNICYCIVE THERAPEUTICS INC

4300 El Camino Real, Suite 210

Los Altos CALIFORNIA US

CEO: Shalabh Gupta

Employees: 14

UNCY Company Website

UNCY Investor Relations

Phone: 16503840642

UNICYCIVE THERAPEUTICS INC / UNCY FAQ

What is the stock price of UNICYCIVE THERAPEUTICS INC today?

The current stock price of UNCY is 0.6371 USD. The price increased by 5.22% in the last trading session.


What is the ticker symbol for UNICYCIVE THERAPEUTICS INC stock?

The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.


On which exchange is UNCY stock listed?

UNCY stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for UNICYCIVE THERAPEUTICS INC stock?

13 analysts have analysed UNCY and the average price target is 6.43 USD. This implies a price increase of 908.63% is expected in the next year compared to the current price of 0.6371. Check the UNICYCIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is UNICYCIVE THERAPEUTICS INC worth?

UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 76.27M USD. This makes UNCY a Micro Cap stock.


How many employees does UNICYCIVE THERAPEUTICS INC have?

UNICYCIVE THERAPEUTICS INC (UNCY) currently has 14 employees.


What are the support and resistance levels for UNICYCIVE THERAPEUTICS INC (UNCY) stock?

UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 0.6 and a resistance level at 0.64. Check the full technical report for a detailed analysis of UNCY support and resistance levels.


Should I buy UNICYCIVE THERAPEUTICS INC (UNCY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UNICYCIVE THERAPEUTICS INC (UNCY) stock pay dividends?

UNCY does not pay a dividend.


When does UNICYCIVE THERAPEUTICS INC (UNCY) report earnings?

UNICYCIVE THERAPEUTICS INC (UNCY) will report earnings on 2025-05-20, after the market close.


What is the Price/Earnings (PE) ratio of UNICYCIVE THERAPEUTICS INC (UNCY)?

UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).


What is the Short Interest ratio of UNICYCIVE THERAPEUTICS INC (UNCY) stock?

The outstanding short interest for UNICYCIVE THERAPEUTICS INC (UNCY) is 0.92% of its float. Check the ownership tab for more information on the UNCY short interest.


UNCY Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is a bad performer in the overall market: 74.01% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

UNCY Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to UNCY. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UNCY Financial Highlights

Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 33.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -119.44%
ROE -509%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)33.54%
Revenue 1Y (TTM)-100%

UNCY Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to UNCY. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners60.39%
Ins Owners6.12%
Short Float %0.92%
Short Ratio1.11
Analysts
Analysts83.08
Price Target6.43 (909.26%)
EPS Next Y74.02%
Revenue Next YearN/A